Artiva Biotherapeutics, Inc. (ARTV) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
1.63
↑+24% vs avg
5yr avg: 1.32
30Y Low1.3·High1.3
ROE
-475.1%
+0% vs avg
5yr avg: -475.1%
30Y Low-475%·High-475%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARTV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Artiva Biotherapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $307M | $246M | — | — | — | — |
| Enterprise Value | $281M | $220M | — | — | — | — |
| P/E Ratio → | -2.41 | — | — | — | — | — |
| P/S Ratio | 1224.31 | 978.41 | — | — | — | — |
| P/B Ratio | 1.63 | 1.32 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARTV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 875.30 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
ARTV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Artiva Biotherapeutics, Inc. earns an operating margin of -26805.6%. Operating margins have compressed from -1213.3% to -26805.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -475.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -26805.6% | -26805.6% | -91.6% | -1213.3% | -2660.9% | — |
| Net Profit Margin | -23304.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -475.1% | -475.1% | — | — | — | — |
| ROA | -37.2% | -37.2% | -23.3% | -38.5% | -72.1% | -61.5% |
| ROIC | — | — | — | — | — | — |
| ROCE | -46.4% | -46.4% | -30.6% | -46.4% | -61.2% | -77.8% |
ARTV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $40M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -91.81 |
Net cash position: cash ($40M) exceeds total debt ($14M)
ARTV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Artiva Biotherapeutics, Inc.'s current ratio of 15.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.08x to 15.39x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 15.39 | 15.39 | 6.53 | 4.08 | 8.41 | 4.53 |
| Quick Ratio | 15.39 | 15.39 | 6.53 | 4.08 | 8.41 | 4.53 |
| Cash Ratio | 15.13 | 15.13 | 6.30 | 4.00 | 8.34 | 4.41 |
| Asset Turnover | — | 0.00 | 0.32 | 0.04 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | 212.31 | 19.16 | 38.86 | 85.32 | — |
ARTV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Artiva Biotherapeutics, Inc. returns 1.4% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 1.4% | 1.7% | — | — | — | — |
| Total Shareholder Yield | 1.4% | 1.7% | — | — | — | — |
| Shares Outstanding | — | $24M | $23M | $18M | $18M | $18M |
Peer Comparison
Compare ARTV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARTVYou | $307M | -2.4 | — | — | 100.0% | -26805.6% | -475.1% | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 STTK | $300M | -8.9 | — | — | -268.8% | -5150.8% | -60.3% | -139.4% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See ARTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARTV vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonARTV — Frequently Asked Questions
Quick answers to the most common questions about buying ARTV stock.
What is Artiva Biotherapeutics, Inc.'s P/E ratio?
Artiva Biotherapeutics, Inc.'s current P/E ratio is -2.4x. This places it at the 50th percentile of its historical range.
What is Artiva Biotherapeutics, Inc.'s ROE?
Artiva Biotherapeutics, Inc.'s return on equity (ROE) is -475.1%. The historical average is -475.1%.
Is ARTV stock overvalued?
Based on historical data, Artiva Biotherapeutics, Inc. is trading at a P/E of -2.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Artiva Biotherapeutics, Inc.'s profit margins?
Artiva Biotherapeutics, Inc. has 100.0% gross margin and -26805.6% operating margin.